392630-77-2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 392630-73-8 4-(2,2-dimethoxyethyl)aniline 
• 4783-65-7 N-benzyl-2-piperidinone 
• 18436-62-9 1-(2,2-Dimethoxyethyl)-4-nitro-benzene 
• 1460-05-5 p-nitrophenylacetaldehyde 

Downstream Products

• 392630-81-8 N-[4-(2,2-dimethoxyethyl)phenyl]-4-piperidinamine 

Relevant academic research and scientific papers

HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

4-Aminopiperidine ureas as potent selective agonists of the human β3-Adrenergic receptor

The preparation and structure-activity relationships (SARs) of potent agonists of the human β3-adrenergic receptor (AR) derived from a 4-aminopiperidine scaffold are described. Examples combine human β3-AR potency with selectivity over human β1-AR and/or human β2-AR agonism. Compound 29s was identified as a potent (EC50 = 1 nM) and selective (greater than 400-fold over β1- with no β2-AR agonism) full β3-AR agonist with in vivo activity in a transgenic mouse model of thermogenesis.